» Articles » PMID: 29534716

Genetic Variation in Clusterin and Risk of Dementia and Ischemic Vascular Disease in the General Population: Cohort Studies and Meta-analyses of 362,338 Individuals

Overview
Journal BMC Med
Publisher Biomed Central
Specialty General Medicine
Date 2018 Mar 15
PMID 29534716
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Clusterin, also known as apolipoprotein J (apoJ), is one of the most abundantly expressed apolipoproteins in the brain after apolipoprotein E (apoE). Like the ε4 allele of the apolipoprotein E gene (APOE), the clusterin gene (CLU) is a risk locus for Alzheimer's disease, and may play additional roles in atherosclerosis pathogenesis. We tested whether genetic variation in CLU was associated with either Alzheimer's disease or atherosclerosis-related diseases.

Methods: We studied individual data on 103,987 participants from the Copenhagen General Population Study (CGPS) and the Copenhagen City Heart Study (CCHS). We genotyped a common CLU variant (rs9331896) and two common APOE variants (rs7412 and rs429358), defining the ε2, ε3, and ε4, alleles in CGPS and CCHS. All individuals in the CGPS and CCHS cohorts were followed from study inclusion to occurrence of event, death, emigration, or until 10 November 2014, whichever came first. Summary consortia data on 258,351 individuals from the International Genomics of Alzheimer's Project (IGAP) and the Coronary Artery Disease Genome-wide Replication and Meta-analysis plus the Coronary Artery Disease (C4D) Genetics and 1000-Genomes-based genome-wide association studies (CARDIoGRAMplusC4D) were used in meta-analyses.

Results: In CGPS and CCHS, multifactorially adjusted hazard ratios for Alzheimer's disease, all dementia, vascular dementia, ischemic cerebrovascular disease, and ischemic heart disease were 1.18 (1.07-1.30), 1.09 (1.02-1.17), 0.96 (0.80-1.17), 1.02 (0.97-1.07), and 0.97 (0.93-1.01) per T allele, respectively. Multifactorially adjusted hazard ratios for Alzheimer's disease and all dementia were 2.72 (2.45-3.01) and 2.21 (2.05-2.38) for the APOE ɛ4 allele. There was no interaction between rs9331896 in CLU and rs429358 (defining the ɛ4 allele) in APOE in predicting Alzheimer's disease or all dementia (P = 0.39 and P = 0.21). In a meta-analysis including consortium data, the overall fixed- and random-effects odds ratios for Alzheimer's disease per T allele were 1.16 (1.13-1.18) (I = 0.0%; P for heterogeneity = 0.89).

Conclusions: A common variant in CLU was associated with a high risk of Alzheimer's disease and all dementia in the general population but not with vascular dementia or ischemic vascular disease. Important novel aspects compared to previous studies are the incorporation of individual risk factor data, the exact causative ε4 allele, and several subtypes of dementia and atherosclerosis-related endpoints.

Citing Articles

Decoding the genetic comorbidity network of Alzheimer's disease.

Zhang X, Li D, Ye S, Liu S, Ma S, Li M BioData Min. 2024; 17(1):40.

PMID: 39385276 PMC: 11465508. DOI: 10.1186/s13040-024-00394-w.


Feasibility of Identifying Factors Related to Alzheimer's Disease and Related Dementia in Real-World Data.

Chen A, Li Q, Huang Y, Li Y, Chuang Y, Hu X medRxiv. 2024; .

PMID: 38405723 PMC: 10889002. DOI: 10.1101/2024.02.10.24302621.


Clinical characteristics of cerebral vascular dementia and early diagnostic value of cranial nuclear magnetic resonance.

Zhou W, Li L, Lang Y, Jiang H Pak J Med Sci. 2023; 39(2):508-512.

PMID: 36950429 PMC: 10025731. DOI: 10.12669/pjms.39.2.6425.


The Role of Clusterin Transporter in the Pathogenesis of Alzheimer's Disease at the Blood-Brain Barrier Interface: A Systematic Review.

Fareed M, Qasmi M, Aziz S, Volker E, Forster C, Shityakov S Biomolecules. 2022; 12(10).

PMID: 36291661 PMC: 9599067. DOI: 10.3390/biom12101452.


Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease.

Nordestgaard L, Christoffersen M, Frikke-Schmidt R Int J Mol Sci. 2022; 23(17).

PMID: 36077172 PMC: 9456552. DOI: 10.3390/ijms23179777.


References
1.
Nordestgaard L, Tybjaerg-Hansen A, Nordestgaard B, Frikke-Schmidt R . Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease. Alzheimers Dement. 2015; 11(12):1430-1438. DOI: 10.1016/j.jalz.2015.04.006. View

2.
Navab M, Van Lenten B, Fonarow G, Cardinez C, Castellani L, Brennan M . Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997; 99(8):2005-19. PMC: 508026. DOI: 10.1172/JCI119369. View

3.
Lidstrom A, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K . Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol. 1999; 154(2):511-21. DOI: 10.1006/exnr.1998.6892. View

4.
Kujiraoka T, Hattori H, Miwa Y, Ishihara M, Ueno T, Ishii J . Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb. 2006; 13(6):314-22. DOI: 10.5551/jat.13.314. View

5.
Phung T, Andersen B, Hogh P, Kessing L, Mortensen P, Waldemar G . Validity of dementia diagnoses in the Danish hospital registers. Dement Geriatr Cogn Disord. 2007; 24(3):220-8. DOI: 10.1159/000107084. View